Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sutro BiopharmaSTRO -4.16%45 Days Sales Outstanding is 84.77 as of Jun. 2026, which is 92% above its 10-year median of 44.09. GuruFocus rates STRO with a GF Score™ of 45/100 and a GF Value™ of $5.50 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 840 Biotechnology companies, Sutro Biopharma ranks better than 62.62% on this metric.
Sutro Biopharma (NAS:STRO) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sutro Biopharma Days Sales Outstanding Related Terms
Sutro Biopharma Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sutro Biopharma's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STRO vs AVIR, IPSC, CCCC: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Sutro Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sutro Biopharma Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sutro Biopharma's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sutro Biopharma's Days Sales Outstanding falls into.
Sutro Biopharma Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sutro Biopharma (STRO) has a Days Sales Outstanding of 84.77 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sutro Biopharma and its competitors. This is 92% above median its historical median of 44.09. Over the past decade, Sutro Biopharma's Days Sales Outstanding has ranged from 3.53 to 131.47. According to the industry distribution chart, Sutro Biopharma ranks #314 out of 840 companies in the Biotechnology industry, placing it in the top 37.4%.
Is Sutro Biopharma's Days Sales Outstanding too high?
Sutro Biopharma's current Days Sales Outstanding of 84.77 is 92% above median its 10-year median of 44.09. Over the past 10 years, this metric has ranged from a low of 3.53 to a high of 131.47. The Biotechnology industry median Days Sales Outstanding is 69.28. Sutro Biopharma's value of 84.77 is 22.4% above this industry median. Based on the distribution chart, Sutro Biopharma ranks #314 out of 840 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sutro Biopharma has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sutro Biopharma's Days Sales Outstanding compare to AVIR and IPSC?
According to the Biotechnology industry distribution chart, Sutro Biopharma ranks #314 out of 840 companies for Days Sales Outstanding. This puts Sutro Biopharma in the upper half of its industry. The industry median Days Sales Outstanding is 69.28. Sutro Biopharma's value of 84.77 is 22.4% above this benchmark. Historically, Sutro Biopharma's own Days Sales Outstanding has ranged from 3.53 to 131.47 over the past decade. While the company's 10-year median is 44.09 vs. the industry median of 69.28, Sutro Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 69.28, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sutro Biopharma's current Days Sales Outstanding of 84.77 is 22.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sutro Biopharma and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 69.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sutro Biopharma's current Days Sales Outstanding is 84.77, which is 92% above median its own 10-year median of 44.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sutro Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sutro Biopharma (STRO) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.50, compared to a current price of $20.46 — trading 272% above its estimated fair value. The current Days Sales Outstanding is 84.77, which is 92% above median its 10-year median of 44.09 and 22.4% above the Biotechnology industry median of 69.28. Sutro Biopharma's overall GF Score™ is 45/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sutro Biopharma (STRO), the current Days Sales Outstanding is 84.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sutro Biopharma (STRO) Overvalued in 2026?
Based on GuruFocus' analysis, Sutro Biopharma stock appears to be overvalued.
The current stock price of $20.46 is trading 272% above its estimated GF Value™ of $5.50.
GuruFocus considers Sutro Biopharma to be Significantly Overvalued.
Key valuation signals for STRO:
Days Sales Outstanding: 84.77 (92% above median its 10-year median of 44.09)
GF Value™: $5.50 vs. price of $20.46 (272% above fair value)
Industry Position: 22.4% above the Biotechnology median (#314 of 840)
No single metric tells the full story. See the STRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
45GF Score
Get the complete analysis for STRO
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STRO has been successfully added to your 
